Примери за използване на Median duration of treatment на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Median duration of treatment(days).
The median duration of treatment was 42 weeks.
Patients received a median of 7 doses of avelumab(range:1 dose to 95 doses), and the median duration of treatment was 17 weeks(range: 2 weeks to 208 weeks).
The median duration of treatment was 9.3 months.
For ovulation induction,Puregon resulted in a lower median total dose and shorter median duration of treatment when compared to urinary FSH.
The median duration of treatment was 28.1 weeks min.
For ovulation induction,follitropin beta resulted in a lower median total dose and shorter median duration of treatment when compared to urinary FSH.
The median duration of treatment in this study was 3.5 days.
At the time of evaluation, median duration of treatment with venetoclax was 14.3 monthsrange.
The median duration of treatment for these patients was 23 weeks.
In post-MI and PAD patients, the median duration of treatment with Zontivity in these patients was 2.5 years(up to 4 years).
The median duration of treatment was 12.9 months(range 0.7 to 47.8 months).
At the time of the analysis of PFS the median duration of treatment was 19.4 months for olaparib and 5.6 months for placebo.
Median duration of treatment was approximately 6 months(range 0.03-31 months).
At the time of the analysis of PFS the median duration of treatment was 8 months for olaparib and 4 months for placebo.
Median duration of treatment was approximately 6 months(range< 1-16 months).
For all treated patients, the median duration of treatment was 2.1 months for the docetaxel arm and 3.4 months for the atezolizumab arm.
Median duration of treatment was approximately 8 months(range< 1- 15 months).
The median duration of treatment with Vizimpro across the pooled data set was 66.7 weeks.
The median duration of treatment in clinical trials was 48 hours(range: 3.5 to 168 hours).
The median duration of treatment with vorapaxar was 823 days(interquartile range: 645-1016 days).
Median duration of treatment was 561 days for CP patients and 264 days for AP patients(see Table 10).
The median duration of treatment was longer for Combo 300 vs Enco 300, 52.1 weeks vs 31.5 weeks.
The median duration of treatment was 13 weeks for the VDDx group and 11 weeks for the VcDx group.
The median duration of treatment for patients who discontinued due to peripheral neuropathy was 12 cycles.
Median duration of treatment on dasatinib was 24 months with 51% of patients treated for> 24 months to date.
Median duration of treatment was 11.7 weeks for first-line patients and 9.0 weeks for previously.
The median duration of treatment with Iclusig was 866 days in CP-CML patients, 590 days in AP-CML patients, and 86 days in BP-CML/Ph+ ALL patients.
Median duration of treatment was 15.0 weeks and median duration of survival follow-up was 8.5 months in all comers.